Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.
Cheng A, Harris S, Giorgino F, Seufert J, Ritzel R, Khunti K, Lauand F, Melas-Melt L, Westerbacka J, Bosnyak Z, Rosenstock J. Cheng A, et al. Among authors: melas melt l. Diabetes Obes Metab. 2020 Mar;22(3):346-354. doi: 10.1111/dom.13901. Epub 2019 Dec 20. Diabetes Obes Metab. 2020. PMID: 31646724 Free PMC article. Clinical Trial.
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
Haluzík M, Cheng A, Müller-Wieland D, Westerbacka J, Bosnyak Z, Lauand F, Melas-Melt L, Karalliedde J, Rosenstock J, Bolli GB. Haluzík M, et al. Among authors: melas melt l. Diabetes Obes Metab. 2020 Aug;22(8):1369-1377. doi: 10.1111/dom.14043. Epub 2020 Apr 28. Diabetes Obes Metab. 2020. PMID: 32243043 Free PMC article. Clinical Trial.
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
Bolli GB, Landgraf W, Bosnyak Z, Melas-Melt L, Home PD. Bolli GB, et al. Among authors: melas melt l. Diabetes Obes Metab. 2020 Sep;22(9):1664-1669. doi: 10.1111/dom.14065. Epub 2020 May 29. Diabetes Obes Metab. 2020. PMID: 32314521 Free PMC article.
Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study.
Wray S, Jacques F, Miller TA, Nicholas JA, Arroyo R, Travis L, Khatri B, Chirieac M, Gandhi R, Roesch N, Rodrigues A, Melas-Melt L, Rawlings AM, Hunter SF. Wray S, et al. Among authors: melas melt l. Mult Scler J Exp Transl Clin. 2022 Nov 15;8(4):20552173221135888. doi: 10.1177/20552173221135888. eCollection 2022 Oct-Dec. Mult Scler J Exp Transl Clin. 2022. PMID: 36407472 Free PMC article.
Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials.
Giorgino F, Guja C, Aydın H, Lauand F, Melas-Melt L, Rosenstock J. Giorgino F, et al. Among authors: melas melt l. Diabetes Res Clin Pract. 2024 Mar;209:111604. doi: 10.1016/j.diabres.2024.111604. Epub 2024 Mar 5. Diabetes Res Clin Pract. 2024. PMID: 38447911 Free article. Clinical Trial.
13 results